Pharmacy Medical News about Glyceollin I

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy
Journal of Pharmacology and Experimental Therapeutics, 10/09/09

Zimmermann MC et al. – The results establish a novel inhibition of ER–mediated gene expression and cell proliferation/survival. Glyceollin I may represent an important component of a phytoalexin–enriched food (activated) diet in terms of chemoprevention as well as a novel therapeutic agent for hormone–dependent tumors.

<< Previous
Critical Cysteine Residues of Kelch-Like ECH-Associated Protein 1...

Next >>
Erythropoietic response to endogenous erythropoietin in premature...

Sensitivity of breast cancer cell lines to recombinant thiaminase I
Cancer Chemotherapy and Pharmacology, 10/20/09 Relevance Score: 46%

Partial Primary Deficiency of Insulin-Like Growth Factor (IGF)-I Activity Associated with IGF1 Mutation Demonstrates Its Critical Role in Growth and Brain Development
Journal of Clinical Endocrinology and Metabolism, 10/12/09 Relevance Score: 46%

Marked high density lipoprotein deficiency due to apolipoprotein A-I Tomioka (codon 138 deletion)
Atherosclerosis, 11/13/09 Relevance Score: 45%

Randomized crossover comparison between the i-gel and the LMA-Unique in anaesthetized, paralysed adults
British Journal of Anesthesia, 10/26/09 Relevance Score: 45%

Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF
American Journal of Hematology, 10/13/09 Relevance Score: 45%